A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Public ClinicalTrials.gov record NCT02634307. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over time in adult participants with RRMS treated with ALKS 8700.
Study identification
- NCT ID
- NCT02634307
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,057 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2015 (Actual)
- Primary completion
- Jun 1, 2021 (Actual)
- Completion
- Nov 11, 2021 (Actual)
- Last update posted
- Jul 26, 2022
2015 – 2021
United States locations
- U.S. sites
- 74
- U.S. states
- 30
- U.S. cities
- 64
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Cullman | Alabama | 35058 | — |
| Alkermes Investigational Site | Phoenix | Arizona | 85004 | — |
| Alkermes Investigational Site | Phoenix | Arizona | 85018 | — |
| Alkermes Investigational Site | Phoenix | Arizona | 85032 | — |
| Alkermes Investigational Site | Tucson | Arizona | 85704 | — |
| Alkermes Investigational Site | Berkeley | California | 94705 | — |
| Alkermes Investigational Site | Loma Linda | California | 92354 | — |
| Alkermes Investigational Site | Long Beach | California | 90806 | — |
| Alkermes Investigational Site | San Diego | California | 92103 | — |
| Alkermes Investigational Site | Basalt | Colorado | 81621 | — |
| Alkermes Investigational Site | Centennial | Colorado | 80111 | — |
| Alkermes Investigational Site | Denver | Colorado | 80209 | — |
| Alkermes Investigational Site | Middlebury | Connecticut | 06762 | — |
| Alkermes Investigational Site | Stamford | Connecticut | 06905 | — |
| Alkermes Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| Alkermes Investigational Site | Atlantis | Florida | 33462 | — |
| Alkermes Investigational Site | Bradenton | Florida | 34209 | — |
| Alkermes Investigational Site | Jacksonville | Florida | 32209 | — |
| Alkermes Investigational Site | Maitland | Florida | 32751 | — |
| Alkermes Investigational Site | Naples | Florida | 34102 | — |
| Alkermes Investigational Site | Ormond Beach | Florida | 32174 | — |
| Alkermes Investigational Site | Sarasota | Florida | 34239 | — |
| Alkermes Investigational Site | Tampa | Florida | 33634 | — |
| Alkermes Investigational Site | Vero Beach | Florida | 32960 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30312-4201 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30327 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30342 | — |
| Alkermes Investigational Site | Columbus | Georgia | 31904 | — |
| Alkermes Investigational Site | Evanston | Illinois | 60201 | — |
| Alkermes Investigational Site | Indianapolis | Indiana | 46202 | — |
| Alkermes Investigational Site | Indianapolis | Indiana | 46260 | — |
| Alkermes Investigational Site | Des Moines | Iowa | 50314 | — |
| Alkermes Investigational Site | Overland Park | Kansas | 66213 | — |
| Alkermes Investigational Site | Lexington | Kentucky | 40513 | — |
| Alkermes Investigational Site | Alexandria | Louisiana | 71301 | — |
| Alkermes Investigational Site | Baton Rouge | Louisiana | 70810 | — |
| Alkermes Investigational Site | Detroit | Michigan | 48202 | — |
| Alkermes Investigational Site | Traverse City | Michigan | 49684 | — |
| Alkermes Investigational Site | Golden Valley | Minnesota | 55422 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63104 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63110 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63131 | — |
| Alkermes Investigational Site | Albuquerque | New Mexico | 87106 | — |
| Alkermes Investigational Site | Patchogue | New York | 11772 | — |
| Alkermes Investigational Site | Plainview | New York | 11803 | — |
| Alkermes Investigational Site | Stony Brook | New York | 11794 | — |
| Alkermes Investigational Site | Syracuse | New York | 13210 | — |
| Alkermes Investigational Site | Charlotte | North Carolina | 28203 | — |
| Alkermes Investigational Site | Greensboro | North Carolina | 27405 | — |
| Alkermes Investigational Site | Raleigh | North Carolina | 27607 | — |
| Alkermes Investigational Site | Winston-Salem | North Carolina | 27103 | — |
| Alkermes Investigational Site | Canton | Ohio | 44718 | — |
| Alkermes Investigational Site | Columbus | Ohio | 43210 | — |
| Alkermes Investigational Site | Dayton | Ohio | 45417 | — |
| Alkermes Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| Alkermes Investigational Site | Medford | Oregon | 97504 | — |
| Alkermes Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Alkermes Investigational Site | Charleston | South Carolina | 29406 | — |
| Alkermes Investigational Site | Greer | South Carolina | 29650 | — |
| Alkermes Investigational Site | Rock Hill | South Carolina | 29732 | — |
| Alkermes Investigational Site | Spartanburg | South Carolina | 29307 | — |
| Alkermes Investigational Site | Cordova | Tennessee | 38018 | — |
| Alkermes Investigational Site | Franklin | Tennessee | 37064 | — |
| Alkermes Investigational Site | Knoxville | Tennessee | 37922 | — |
| Alkermes Investigational Site | Dallas | Texas | 75231 | — |
| Alkermes Investigational Site | Houston | Texas | 77030 | — |
| Alkermes Investigational Site | Houston | Texas | 77074 | — |
| Alkermes Investigational Site | Lubbock | Texas | 79410 | — |
| Alkermes Investigational Site | Salt Lake City | Utah | 84103 | — |
| Alkermes Investigational Site | Newport News | Virginia | 23601 | — |
| Alkermes Investigational Site | Richmond | Virginia | 23228 | — |
| Alkermes Investigational Site | Seattle | Washington | 98101 | — |
| Alkermes Investigational Site | Seattle | Washington | 98122 | — |
| Alkermes Investigational Site | Seattle | Washington | 98133 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02634307, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2022 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02634307 live on ClinicalTrials.gov.